Positive Patient Stories™

Paratek Pharmaceuticals News

Webcast ImageWebcast
2018 Paratek Investor Day (Replay)
10/23/18 at 12:00 p.m. ET
2018 Paratek Investor Day
Tuesday, October 23, 2018 12:00 p.m. ET  through Tuesday, October 23, 2018 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Paratek Pharmaceuticals Inc Q3 2018 Earnings Conference Call  (Replay)
11/06/18 at 4:30 p.m. ET
Paratek Pharmaceuticals Inc Q3 2018 Earnings Conference Call
Tuesday, November 6, 2018 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle  
11/06/18Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results 
11/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
10/26/18Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018 
10/04/18Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline 
10/03/18Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018 
10/02/18Paratek Announces FDA Approval of NUZYRA™ (Omadacycline) 
10/02/18FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne 
10/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
09/25/18Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018 
09/04/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
08/29/18Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference 
08/08/18FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline 
08/08/18Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections 
08/02/18Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results 
07/23/18Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018 
06/20/18Paratek Announces FDA Advisory Committee Date for Omadacycline 
06/11/18Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018 
06/07/18Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018 
06/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
05/22/18Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity 
05/09/18Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results 
05/01/18Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 
04/25/18Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018 
04/23/18Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID 
04/23/18Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections 
04/19/18Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024 
04/18/18Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024 
04/13/18Paratek Appoints Rolf K. Hoffmann to Company’s Board of Directors 
04/12/18Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018 
04/04/18Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA 
03/30/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
03/28/18Paratek Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference 
03/16/18Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference 
03/02/18Paratek Pharmaceuticals to Present at the 38th Annual Cowen & Co. Health Care Conference 
03/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
03/01/18Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019 
02/15/18Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018 
02/05/18Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections 
02/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
01/31/18Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare Conference 
01/18/18Paratek Announces Pricing of Public Offering of Common Stock 
01/17/18Paratek Announces Public Offering of Common Stock 
01/03/18Paratek Provides Update on Pipeline Progress 

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.